<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737604</url>
  </required_header>
  <id_info>
    <org_study_id>1205738</org_study_id>
    <nct_id>NCT03737604</nct_id>
  </id_info>
  <brief_title>TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant</brief_title>
  <official_title>Transversus Abdominis Plane (TAP) Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine: A Prospective Randomized Control Trial for Pain Control After Renal Transplant Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a comparison of the analgesic efficacy of transversus abdominis plane (TAP)
      blocks with ropivacaine bolus plus continuous ropivacaine infusion via catheters versus
      single shot TAP blocks with liposomal bupivacaine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a comparison of the analgesic efficacy of TAP blocks provided by ropivacaine
      bolus plus continuous ropivacaine infusion via catheters versus single shot TAP blocks with
      liposomal bupivacaine.

      In the Liposomal Bupivacaine group, TAP block will be performed using ultrasound guidance.
      12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP.
      Liposomal Bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of
      preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected
      into the TAP.

      For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP
      block and 5 mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter
      will be placed approximately 3-5 cm into the TAP space after injection of ropivacaine. A
      bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a
      maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8
      ml/hr of 0.2% ropivacaine on the inpatient floor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Unable to mask based on physical characteristics of liposomal bupivacaine</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Total Opioid Consumption</measure>
    <time_frame>Through 4 days following renal transplant surgery</time_frame>
    <description>Total amount of opioid analgesic administered following renal transplant surgery converted using standard equivalency calculations to morphine equivalents mg/kg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of pain scores indicating severe pain</measure>
    <time_frame>Through 4 days following renal transplant surgery</time_frame>
    <description>Proportion of pain scores 7 or higher indicating severe pain as determined by patient report of pain using verbal pain score from 0 (no pain) to10 (most severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Nausea</measure>
    <time_frame>Through 4 days following renal transplant surgery</time_frame>
    <description>Count of post operative nausea episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Vomiting</measure>
    <time_frame>Through 4 days following renal transplant</time_frame>
    <description>Count of post operative vomiting events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Depression</measure>
    <time_frame>Through 4 days following renal transplant surgery</time_frame>
    <description>Count of Respiratory Depression events defined as respiratory rate less than 8 breaths per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Care Unit and Hospital Length of Stay</measure>
    <time_frame>Up to 2 weeks following renal transplant surgery</time_frame>
    <description>Length of Stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquisition Costs Related to Analgesia</measure>
    <time_frame>Up to 2 weeks following renal transplant surgery</time_frame>
    <description>Analgesia Related Costs defined as the sum of hospital specific costs to acquire medications and supplies needed to perform block or administer analgesic and local anesthetic medications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Transplant;Failure,Kidney</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Ropivacaine Continuous Infusion Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine Continuous Infusion Catheter: ultrasound guided TAP block and TAP catheter placement performed with 0.2% ropivacaine (2.5 mg/kg) and maintained with 0.2% ropivacaine infusion 8 ml/hour via catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose liposomal bupivicaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal bupivacaine TAP block: ultrasound guided TAP block a performed with up to 12 ml 0.25% bupivacaine and prolonged with liposomal bupivacaine 133 mg diluted to total volume of 20 ml with preservative free saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine Continuous Infusion Catheter</intervention_name>
    <description>For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.</description>
    <arm_group_label>Ropivacaine Continuous Infusion Catheter</arm_group_label>
    <other_name>TAP block initiated with ropivacaine bolus and infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single Dose Liposomal Bupivicaine</intervention_name>
    <description>TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.</description>
    <arm_group_label>Single dose liposomal bupivicaine</arm_group_label>
    <other_name>TAP block with liposomal bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ages 18 years or older

          -  Renal Transplant Recipients

        Exclusion Criteria:

          -  Patients less than 18 years of age

          -  Pregnant Women

          -  Prisoners

          -  Opioid Tolerant Patients taking more than 30 mg/day of oral morphine equivalent
             analgesia

          -  Patients on Systemic anti coagulation

          -  Patients unable to provide consent

          -  Hypersensitivity to amide-type local anesthetic or any component of the drug formula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana Arias, BS</last_name>
    <phone>916-703-5456</phone>
    <email>apaarias@ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natasha Piniero, BS</last_name>
    <phone>916-734-5171</phone>
    <email>nspiniero@ucdavis.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Arias, BS</last_name>
      <phone>916-703-5456</phone>
      <email>apaarias@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natasha Piniero, BS</last_name>
      <phone>916-734-5171</phone>
      <email>nspiniero@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Applegate, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transversus Abdominis Plane Block</keyword>
  <keyword>Ropivacaine</keyword>
  <keyword>Liposomal bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

